Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
– Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 –
– Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 –
ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq:VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”). The Company is targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025.
Related news for (VIRI)
- virios therapeutics, inc. and wex pharmaceuticals, inc. announce business combination to form dogwood therapeutics, inc. (nasdaq: “dwtx”)
- Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
- Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023